Genome & Company's largest shareholder Park Han-su's stake plunges from 15.67% to 9.65% due to gifts and dilution from new share issuance, raising dilution risk
Park Han-su, the largest shareholder and co-CEO of Genome & Company, gifted 20,000 shares to an employee while the total outstanding shares increased from 32,829,381 to 54,451,812 (approx. 66% increase), causing his stake to plummet from 15.67% to 9.65%.
The dilution from new share issuance is dominant, implying value dilution for existing shareholders. The largest shareholder's stake falling below 10% raises questions about management control stability.
Including special relations (e.g., Hong Yoo-seok with 1.8 million stock options, Park Jae-yeon with 320,000 stock options, totaling 2.12 million potential shares), the effective control is only about 9.65%.
[AI Comprehensive Analysis]This filing confirms a sharp decline in the largest shareholder's stake due to dilution from new share issuance and a gift. It is likely to negatively impact the stock price in the short term and raises concerns about governance stability.